New Under-the-Tongue pill aims to help men last longer

NCT ID NCT07434271

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study tests a new drug called KH-001, taken as a fast-dissolving tablet under the tongue 15 minutes before sex, to see if it helps men with lifelong premature ejaculation last longer. About 40 men in stable relationships will try the drug or a placebo for 4 weeks each, with a break in between. The main goal is to measure changes in how long they can delay ejaculation using a stopwatch held by their partner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
KH-001 (a besylate drug in a fast-dissolving tablet taken under the tongue before sex)
What this could lead to
If it works, this could offer a new on-demand treatment to help men with lifelong premature ejaculation last longer during intercourse.
What could go wrong
This is an early Phase 2 study with only 40 men, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male participants aged 18 to 65 years (inclusive) at the time of informed consent. 2. In a stable (≥6 months) monogamous heterosexual relationship. 3. Self-reported lifelong premature ejaculation (LPE), meeting the ISSM definition. 4. Intravaginal Ejaculatory Latency Time (IELT) ≤1 minute on at least 75% of intercourse attempts during the 4-week run-in period. 5. PEDT (Premature Ejaculation Diagnostic Tool) score ≥11. 6. Normal erectile function (IIEF Questions 1-5 sum score ≥21). 7. Personal distress rated at least "moderate" on the Premature Ejaculation Profile (PEP) after the run-in period. 8. In good general health and medically stable as per investigator's judgment. 9. Willing to attempt intercourse at least 4 times during each 4-week treatment period. 10. For partners of childbearing potential: agreement to use acceptable contraception methods from Screening until 30 days post last dose. 11. Willing to avoid sperm donation from first dose until at least 90 days after the last dose. 12. Willing to limit alcohol intake on dosing days. 13. Ability to provide written informed consent and comply with study requirements. Exclusion Criteria: 1. IELT \>1 minute on more than 25% of attempts during the run-in period. 2. Fewer than 4 intercourse attempts during the run-in period. 3. Self-rated control of ejaculation as fair, good, or very good on the PEP. 4. Low personal distress ("not at all" or "a little bit") on the PEP. 5. Erectile dysfunction (IIEF Questions 1-5 sum score \<21). 6. Significant anatomical penile deformities or history of penile surgery affecting erection. 7. History of other forms of sexual dysfunction. 8. Untreated or unstable thyroid dysfunction. 9. Recent use (within 4 weeks) of SSRIs, SNRIs, PDE5 inhibitors, MAO inhibitors, alpha blockers, 5-alpha reductase inhibitors, topical anesthetics, or tramadol. 10. History of sexual dysfunction treatments like Botox for PE in the past 6 months. 11. Active or uncontrolled sexually transmitted infections. 12. Severe psychiatric disorders, major depression, or suicidal ideation. 13. Clinically significant laboratory abnormalities or cardiovascular risk factors. 14. Positive drug screen (unless explained by prescription use). 15. Positive for HIV, Hepatitis B, or Hepatitis C. 16. Planned major surgery during study period. 17. BMI outside 18.0-35.0 kg/m² or weight \<50 kg.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Premature ejaculation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emeritus Research Sydney

    RECRUITING

    Botany, New South Wales, 2019, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.